Cite
HARVARD Citation
Bilusic, M. et al. (2021). Phase I study of a multitargeted recombinant Ad5 PSA/MUC-1/brachyury-based immunotherapy vaccine in patients with metastatic castration-resistant prostate cancer (mCRPC). Journal for immunotherapy of cancer. 9 (3), p. . [Online].